Citadel Advisors’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.1M | Buy |
2,876,200
+2,535,200
| +743% | +$17.4M | ﹤0.01% | 2215 |
|
|
2025
Q4 | $675K | Sell |
341,000
-189,500
| -36% | -$429K | ﹤0.01% | 8281 |
|
|
2025
Q3 | $1.31M | Buy |
530,500
+92,000
| +21% | +$237K | ﹤0.01% | 6966 |
|
|
2025
Q2 | $1.16M | Buy |
438,500
+51,100
| +13% | +$137K | ﹤0.01% | 6763 |
|
|
2025
Q1 | $1.17M | Buy |
387,400
+143,400
| +59% | +$435K | ﹤0.01% | 6618 |
|
|
2024
Q4 | $625K | Buy |
244,000
+82,000
| +51% | +$342K | ﹤0.01% | 8059 |
|
|
2024
Q3 | $603K | Sell |
162,000
-175,500
| -52% | -$812K | ﹤0.01% | 7865 |
|
|
2024
Q2 | $2.13M | Sell |
337,500
-105,900
| -24% | -$698K | ﹤0.01% | 5185 |
|
|
2024
Q1 | $2.38M | Buy |
443,400
+348,000
| +365% | +$1.58M | ﹤0.01% | 5187 |
|
|
2023
Q4 | $479K | Sell |
95,400
-73,100
| -43% | -$229K | ﹤0.01% | 8215 |
|
|
2023
Q3 | $285K | Sell |
168,500
-104,200
| -38% | -$209K | ﹤0.01% | 9271 |
|
|
2023
Q2 | $758K | Buy |
272,700
+6,500
| +2% | +$18.4K | ﹤0.01% | 7036 |
|
|
2023
Q1 | $484K | Sell |
266,200
-39,200
| -13% | -$122K | ﹤0.01% | 8387 |
|
|
2022
Q4 | $1.55M | Buy |
305,400
+99,000
| +48% | +$544K | ﹤0.01% | 5975 |
|
|
2022
Q3 | $1.03M | Buy |
206,400
+67,100
| +48% | +$306K | ﹤0.01% | 6930 |
|
|
2022
Q2 | $518K | Buy |
139,300
+50,400
| +57% | +$202K | ﹤0.01% | 8566 |
|
|
2022
Q1 | $499K | Sell |
88,900
-8,600
| -9% | -$52.8K | ﹤0.01% | 9406 |
|
|
2021
Q4 | $593K | Buy |
97,500
+23,700
| +32% | +$178K | ﹤0.01% | 9254 |
|
|
2021
Q3 | $719K | Sell |
73,800
-39,300
| -35% | -$432K | ﹤0.01% | 8998 |
|
|
2021
Q2 | $1.61M | Buy |
113,100
+7,800
| +7% | +$129K | ﹤0.01% | 7133 |
|
|
2021
Q1 | $2.5M | Buy |
105,300
+15,000
| +17% | +$389K | ﹤0.01% | 5877 |
|
|
2020
Q4 | $1.2M | Buy |
90,300
+3,800
| +4% | +$36.6K | ﹤0.01% | 6404 |
|
|
2020
Q3 | $600K | Sell |
86,500
-22,800
| -21% | -$227K | ﹤0.01% | 6957 |
|
|
2020
Q2 | $1.34M | Buy |
109,300
+70,700
| +183% | +$399K | ﹤0.01% | 5285 |
|
|
2020
Q1 | $111K | Buy |
38,600
+27,600
| +251% | +$138K | ﹤0.01% | 8563 |
|
|
2019
Q4 | $42K | Buy |
+11,000
| New | +$18.7K | ﹤0.01% | 8798 |
|
|
2019
Q2 | – | Sell |
-27,400
| Closed | -$43K | – | 9471 |
|
|
2019
Q1 | $43K | Sell |
27,400
-13,600
| -33% | -$17.1K | ﹤0.01% | 8881 |
|
|
2018
Q4 | $48K | Buy |
+41,000
| New | +$93.8K | ﹤0.01% | 8498 |
|
|
2018
Q2 | – | Sell |
-12,000
| Closed | -$47K | – | 9021 |
|
|
2018
Q1 | $47K | Buy |
+12,000
| New | +$52.6K | ﹤0.01% | 7938 |
|
|
2017
Q4 | – | Sell |
-21,100
| Closed | -$116K | – | 8181 |
|
|
2017
Q3 | $116K | Sell |
21,100
-9,200
| -30% | -$56.7K | ﹤0.01% | 6982 |
|
|
2017
Q2 | $230K | Buy |
+30,300
| New | +$131K | ﹤0.01% | 6350 |
|
|
2016
Q4 | – | Sell |
-15,900
| Closed | -$124K | – | 7508 |
|
|
2016
Q3 | $124K | Sell |
15,900
-5,300
| -25% | -$39.6K | ﹤0.01% | 6565 |
|
|
2016
Q2 | $132K | Buy |
+21,200
| New | +$165K | ﹤0.01% | 6075 |
|
|
2016
Q1 | – | Sell |
-3,300
| Closed | -$57K | – | 7295 |
|
|
2015
Q4 | $57K | Buy |
3,300
+1,800
| +120% | +$26.7K | ﹤0.01% | 7199 |
|
|
2015
Q3 | $17K | Buy |
+1,500
| New | +$32.7K | ﹤0.01% | 8255 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Citadel Advisors's IBRX Position: Q1 2026 in Review
Citadel Advisors reduced its ImmunityBio (IBRX) stake by 57% in Q1 2026, selling an estimated $2.73M and leaving 305,578 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5752.
Citadel Advisors first reported a position in IBRX in Q3 2015 and has held it in 30 quarters since. The position peaked at $6.27M in Q2 2020. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Citadel Advisors held 305,578 shares of ImmunityBio worth $2.34M as of Q1 2026.
- Citadel Advisors sold 398,996 ImmunityBio shares in Q1 2026, an estimated $2.73M.
- ImmunityBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5752 holding.
- Citadel Advisors first reported a position in ImmunityBio in Q3 2015 and has held it in 30 quarters since.
- Citadel Advisors's ImmunityBio position peaked at $6.27M in Q2 2020.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.